Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free IMCC Stock Alerts

IM Cannabis (IMCC) Competitors

IM Cannabis logo
$0.13 +0.01 (+4.25%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$0.13 0.00 (-0.77%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

IMCC vs. GRI, CASI, SNYR, DCOY, and GOVX

Should you buy IM Cannabis stock or one of its competitors? IM Cannabis's main competitors and comparable companies include GRI Bio (GRI), CASI Pharmaceuticals (CASI), Synergy CHC (SNYR), Decoy Therapeutics (DCOY), and GeoVax Labs (GOVX). Companies are selected based on similarities in market, industry, and size.

How does IM Cannabis compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

GRI Bio currently has a consensus target price of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts clearly believe GRI Bio is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, GRI Bio and GRI Bio both had 1 articles in the media. GRI Bio's average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRI Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IM Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GRI Bio has a beta of -1.2, meaning that its stock price is 220% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

GRI Bio has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. GRI Bio's return on equity of -199.52% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -199.52% -143.23%
IM Cannabis -27.65%-585.96%-39.96%

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IM Cannabis has higher revenue and earnings than GRI Bio. IM Cannabis is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$11.96M-$74.16N/A
IM Cannabis$39.17M0.02-$8.10M-$1.75N/A

Summary

GRI Bio beats IM Cannabis on 8 of the 13 factors compared between the two stocks.

How does IM Cannabis compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

IM Cannabis has a net margin of -27.65% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
CASI Pharmaceuticals-183.93% N/A -131.54%
IM Cannabis -27.65%-585.96%-39.96%

In the previous week, IM Cannabis had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company Overall Sentiment
CASI Pharmaceuticals Neutral
IM Cannabis Neutral

IM Cannabis has higher revenue and earnings than CASI Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CASI Pharmaceuticals$26.85M0.10-$39.26M-$3.01N/A
IM Cannabis$39.17M0.02-$8.10M-$1.75N/A

CASI Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe CASI Pharmaceuticals is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CASI Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market.

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

CASI Pharmaceuticals beats IM Cannabis on 8 of the 15 factors compared between the two stocks.

How does IM Cannabis compare to Synergy CHC?

Synergy CHC (NASDAQ:SNYR) and IM Cannabis (NASDAQ:IMCC) are related small-cap companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Synergy CHC has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than Synergy CHC. Synergy CHC is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synergy CHC$30.38M0.08-$12.34M-$1.40N/A
IM Cannabis$39.17M0.02-$8.10M-$1.75N/A

In the previous week, IM Cannabis had 1 more articles in the media than Synergy CHC. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for Synergy CHC. Synergy CHC's average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company Overall Sentiment
Synergy CHC Neutral
IM Cannabis Neutral

IM Cannabis has a net margin of -27.65% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Synergy CHC-60.02% N/A -30.30%
IM Cannabis -27.65%-585.96%-39.96%

Synergy CHC currently has a consensus price target of $6.25, indicating a potential upside of 3,685.58%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities research analysts clearly believe Synergy CHC is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synergy CHC
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

7.7% of IM Cannabis shares are owned by institutional investors. 32.9% of Synergy CHC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Synergy CHC beats IM Cannabis on 8 of the 15 factors compared between the two stocks.

How does IM Cannabis compare to Decoy Therapeutics?

IM Cannabis (NASDAQ:IMCC) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IM Cannabis has higher revenue and earnings than Decoy Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.17M0.02-$8.10M-$1.75N/A
Decoy TherapeuticsN/AN/A-$12.52M-$106.90N/A

In the previous week, IM Cannabis had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for Decoy Therapeutics. IM Cannabis' average media sentiment score of 0.00 equaled Decoy Therapeutics'average media sentiment score.

Company Overall Sentiment
IM Cannabis Neutral
Decoy Therapeutics Neutral

Decoy Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Decoy Therapeutics' return on equity of -395.42% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-27.65% -585.96% -39.96%
Decoy Therapeutics N/A -395.42%-193.30%

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 683.29%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Decoy Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

IM Cannabis has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Summary

Decoy Therapeutics beats IM Cannabis on 8 of the 14 factors compared between the two stocks.

How does IM Cannabis compare to GeoVax Labs?

IM Cannabis (NASDAQ:IMCC) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 19,793.90%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

GeoVax Labs has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-27.65% -585.96% -39.96%
GeoVax Labs N/A -743.64%-394.74%

IM Cannabis has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.73, meaning that its share price is 273% more volatile than the broader market.

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IM Cannabis has higher revenue and earnings than GeoVax Labs. IM Cannabis is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.17M0.02-$8.10M-$1.75N/A
GeoVax Labs$2.49M1.05-$21.47M-$11.34N/A

In the previous week, IM Cannabis and IM Cannabis both had 1 articles in the media. IM Cannabis' average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IM Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GeoVax Labs
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

GeoVax Labs beats IM Cannabis on 7 of the 13 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCC vs. The Competition

Export
MetricIM CannabisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$780K$11.81B$7.01B$12.98B
Dividend YieldN/A2.69%2.58%10.06%
P/E Ratio-0.07788.51269.1824.72
Price / Sales0.02743.73585.5796.21
Price / CashN/A15.1228.8937.42
Price / Book-0.2710.2611.406.42
Net Income-$8.10M$2.77B$3.45B$347.03M
7 Day Performance2.36%0.82%1.96%0.71%
1 Month Performance-16.13%-1.63%-0.55%-0.87%
1 Year Performance-95.56%183.16%75.51%21.94%

IM Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCC
IM Cannabis
0.3504 of 5 stars		$0.13
+4.3%		N/A-95.3%$780K$39.17MN/A340
GRI
GRI Bio
1.8507 of 5 stars		$1.46
-0.4%		$32.00
+2,085.8%		-95.2%$2.59MN/AN/A1
CASI
CASI Pharmaceuticals
N/A$0.21
flat		$4.00
+1,827.7%		N/A$2.55M$26.85MN/A180
SNYR
Synergy CHC
2.5198 of 5 stars		$0.17
-1.3%		$6.25
+3,609.2%		-95.3%$2.54M$30.38MN/A40
DCOY
Decoy Therapeutics
2.5328 of 5 stars		$4.24
+5.1%		$30.00
+608.4%		N/A$2.50MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IMCC) was last updated on 8/11/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel